Article Text

Download PDFPDF

1264 Recognition and management of immunotherapy toxicity: a quality improvement project
  1. Shree Spandana Ghanta1,
  2. Kavya Nalluri1,
  3. Oluwatayo Adeoye1 and
  4. Olga Kozyreva2
  1. 1St. Elizabeths Medical Center, Brighton, MA, USA
  2. 2Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center, boston, MA, USA


Background Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer treatment over the past decade. With broaden ICIs use, internal medicine physicians are increasingly encountering them. Our study aims to assess Internal Medicine Resident’s (IMR) knowledge on immune related adverse events irAEs and identify potential gaps

Methods We designed 21-questions pre-intervention survey in January 2022 assessing IMR knowledge of ICIs and associated irAEs. It assessed the following components regarding ICIs and irAEs: (1) recognition of ICIs, (2) recognition of organ systems associated with irAEs, (3) common timeframe of irAEs, (4) initial management strategies for irAEs, (5) common misconceptions about irAEs, and (6) self-rated physician comfort level on recognition/treatment of irAE. Teaching sessions by medical oncology attending and QI project team residents were conducted after survey. 21-questions post-intervention survey was sent to IMR in September 2022. The results of the surveys were compared.

Results 42 of 57IMRs (73.7%) participated in pre-intervention survey and 45 of 57IMRs (78.9%) participated in post-intervention survey (tables 1 and 2).

Limitations: The length of the survey limited our ability to test regarding a wide variety of ICIs and irAEs.

Conclusions We identified the knowledge gaps regarding ICIs and irAEs among IMRs. Educational content provided in multiple formats demonstrated increased knowledge. IMRs may benefit from web-based learning tools and algorithms on ICIs/irAEs management.

Abstract 1264 Table 1

Confidence level in recognizing/managing irAEs on scale of 1–5

Abstract 1264 Table 2

Knowledge of irAEs

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.